RINVOQ

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, South Africa, Spain, Turkey, UK.

Active ingredients

The drug RINVOQ contains one active pharmaceutical ingredient (API):

1	Upadacitinib UNII NEW4DV02U5 - UPADACITINIB HEMIHYDRATE
	Upadacitinib is a selective and reversible Janus kinase (JAK) inhibitor. In human cellular assays, upadacitinib preferentially inhibits signalling by JAK1 or JAK1/3 with functional selectivity over cytokine receptors that signal via pairs of JAK2. JAK1 is important in inflammatory cytokine signals while JAK2 is important for red blood cell maturation and JAK3 signals play a role in immune surveillance and lymphocyte function.
	Read more about Upadacitinib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
RINVOQ Extended-release tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)
RINVOQ Prolonged-release tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AF03		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AF Janus-associated kinase (JAK) inhibitors
Discover more medicines within L04AF03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	11979L, 11989B
BR	Câmara de Regulação do Mercado de Medicamentos	543720060004207, 543720060004307
CA	Health Products and Food Branch	02495155
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	5591-MEE-1020, 7080-MEE-0322
EE	Ravimiamet	1808951, 1808962, 1808973, 1809312, 1809323, 1860588, 1860601, 1860612, 1860623, 1887857, 1887891
ES	Centro de información online de medicamentos de la AEMPS	1191404001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	091893
FR	Base de données publique des médicaments	65852428
GB	Medicines & Healthcare Products Regulatory Agency	380675
HK	Department of Health Drug Office	66872
IE	Health Products Regulatory Authority	89057, 89155
IL	מִשְׂרַד הַבְּרִיאוּת	8740, 9072, 9307
IT	Agenzia del Farmaco	048399012, 048399024, 048399036, 048399048, 048399051, 048399063, 048399075, 048399087, 048399099, 048399101, 048399113
JP	医薬品医療機器総合機構	3999048G1028, 3999048G2024, 3999048G3020, 3999048G4027
LT	Valstybinė vaistų kontrolės tarnyba	1089080, 1089081, 1089082, 1089083, 1089084, 1093301, 1093302, 1093303, 1093304
NL	Z-Index G-Standaard, PRK	201073
NZ	Medicines and Medical Devices Safety Authority	20573, 22034
PL	Rejestru Produktów Leczniczych	100427770
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W66589001, W68028001, W69486001, W69486002
TR	İlaç ve Tıbbi Cihaz Kurumu	8680656080575, 8680656080582
US	FDA, National Drug Code	0074-2306
ZA	Health Products Regulatory Authority	54/3.1/0187